Exelixis: Truist raises price target citing increased sales potential

Published 2025-01-14, 11:06 p/m
© Reuters.
EXEL
-

Investing.com-- Truist analysts have increased their price target (PT) for Exelixis Inc (NASDAQ:EXEL), reflecting greater confidence in the company’s growth prospects.

Exelixis, a biotechnology firm specializing in oncology treatments, continues to gain momentum with its flagship drug, Cabometyx, and its promising pipeline, Truist analysts said in a note.

The brokerage raised PT to $42 from $38 while retaining a "Buy" rating.

The analysts cited expanded sales potential for Cabometyx in treating neuroendocrine tumors (NET) as a key factor in the updated valuation. They now estimate peak sales for this indication to reach approximately $700 million, while Exelixis projects a potential market size of $1 billion.

Recent inclusion in the National Comprehensive Cancer Network (NCCN) guidelines has bolstered confidence in the drug’s broader uptake, analysts said.

Truist also highlighted Exelixis’ upcoming catalysts for Zanza, a newer therapy derived from Cabometyx. Zanza has three significant value-driving milestones anticipated in 2025, which could further enhance its growth outlook and justify additional upward revisions to the price target.

"While the biotech markets are choppy, we think investors will find comfort in the stability of EXEL's revenue generating & growing base biz, layered with catalyst upsides, making this a very investable name in 2025, in our view," analysts wrote

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.